FDA says compounding pharmacies can keep making weight-loss med tirzepatide, for now
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list.
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
A weight-loss drug more effective than Ozempic and Wegovy has recently been approved. Here’s how it works and how it compares ...
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...
Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
The British government is set to explore whether Eli Lilly’s weight-loss drug could play a pivotal role in getting people ...
The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback